Distinguished in Polymyalgia Rheumatica

Aleth Perdriger

CHU De Reims
Reims, FR 
Distinguished in Polymyalgia Rheumatica
CHU De Reims
Reims, FR 
OverviewLocationsClinical Research

Overview

Aleth Perdriger practices in Reims, France. Perdriger is rated as a Distinguished expert by MediFind in the treatment of Polymyalgia Rheumatica. Their top areas of expertise are Whipple Disease, Actinomycosis, Sjogren Syndrome, and Dry Mouth.

Their clinical research consists of co-authoring 69 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 4 articles and participated in 1 clinical trial in the study of Polymyalgia Rheumatica.

Locations

CHU de Reims
Reims, 51092, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Pragmatic Study Comparing the Clinical Evlauation Methods ( C) and / or Ultrasound Method ( B or D) in Rheumatoid Arthritis (RA) to Adapt Treatment
Pragmatic Study Comparing the Clinical Evlauation Methods ( C) and / or Ultrasound Method ( B or D) in Rheumatoid Arthritis (RA) to Adapt Treatment
Enrollment Status: Completed
Publish Date: December 12, 2023
Intervention Type: Device
Study Phase: Not Applicable
Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis
Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: August 09, 2021
Intervention Type: Drug
Study Phase: Phase 4
Relationship Between T LYmphocytes Depletion and Clinical Response to RITUXimab in Rheumatoid Arthritis (LYRITUX)
Relationship Between T LYmphocytes Depletion and Clinical Response to RITUXimab in Rheumatoid Arthritis (LYRITUX)
Enrollment Status: Completed
Publish Date: May 06, 2021
Intervention Type: Drug
Study Drug: Rituximab
Study Phase: Phase 3
Safety and Efficacy of tocilizuMAb Versus Placebo in Polymyalgia rHeumatica With glucocORticoid dEpendence SEMAPHORE
Safety and Efficacy of tocilizuMAb Versus Placebo in Polymyalgia rHeumatica With glucocORticoid dEpendence SEMAPHORE
Enrollment Status: Completed
Publish Date: December 04, 2020
Intervention Type: Drug
Study Phase: Phase 3
Lead Time of the Methotrexate Establishment and Vaccinal Protection Against the Pneumococcal Agent in Patients Affected With Rheumatoid Polyarthritis
Lead Time of the Methotrexate Establishment and Vaccinal Protection Against the Pneumococcal Agent in Patients Affected With Rheumatoid Polyarthritis
Enrollment Status: Completed
Publish Date: August 03, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 3
View 4 Less Clinical Trials

69 Total Publications

Maintenance of Remission After Tocilizumab Withdrawal in Patients With Glucocorticoid-Dependent Polymyalgia Rheumatica.
Maintenance of Remission After Tocilizumab Withdrawal in Patients With Glucocorticoid-Dependent Polymyalgia Rheumatica.
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: December 23, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Perdriger's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 24 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile